Anticoagulant-associated intracerebral hemorrhage

Seminars in Neurology

Volumn 30, Issue 5, 2010, Pages 565-572

  Flaherty, Matthew L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

anticoagulants; epidemiology; Intracerebral hemorrhage; warfarin

Indexed keywords

FRESH FROZEN PLASMA; HEPARIN; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; CLINICAL FEATURE; CONTROLLED STUDY; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; NEUROSURGICAL PROCEDURES; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650964099     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1268866     Document Type: Article

References (88)

1. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990 21 4 637-676
2. Kleindorfer D O., Khoury J, Moomaw C J. et al. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study. Stroke 2010 41 7 1326-1331
3. Flaherty M L., Haverbusch M, Sekar P et al. Long-term mortality after intracerebral hemorrhage. Neurology 2006 66 8 1182-1186
4. Dennis M S. Outcome after brain haemorrhage. Cerebrovasc Dis 2003 16 Suppl 1 9-13
5. Kissela B, Schneider A, Kleindorfer D et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke 2004 35 2 426-431
6. Flaherty M L., Woo D, Haverbusch M et al. Racial variations in location and risk of intracerebral hemorrhage. Stroke 2005 36 5 934-937
7. Fogelholm R, Nuutila M, Vuorela A L. Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome. J Neurol Neurosurg Psychiatry 1992 55 7 546-552
8. Brown R D. Jr, Whisnant J P., Sicks J D., O'Fallon W M., Wiebers D O. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996 27 3 373-380
9. Tanaka H, Ueda Y, Date C et al. Incidence of stroke in Shibata, Japan: 1976-1978. Stroke 1981 12 4 460-466
10. Inagawa T, Ohbayashi N, Takechi A, Shibukawa M, Yahara K. Primary intracerebral hemorrhage in Izumo City, Japan: incidence rates and outcome in relation to the site of hemorrhage. Neurosurgery 2003 53 6 1283-1297, discussion 1297-1298
11. Morgenstern L B., Smith M A., Lisabeth L D. et al. Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol 2004 160 4 376-383
12. Labovitz D L., Halim A, Boden-Albala B, Hauser W A., Sacco R L. The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and Hispanics. Neurology 2005 65 4 518-522
13. Woo D, Haverbusch M, Sekar P et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004 35 7 1703-1708
14. Woo D, Sauerbeck L R., Kissela B M. et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002 33 5 1190-1195
15. Hemphill J C. III, Bonovich D C., Besmertis L, Manley G T., Johnston S C. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001 32 4 891-897
16. Broderick J P., Brott T G., Duldner J E., Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993 24 7 987-993
17. Rosand J, Eckman M H., Knudsen K A., Singer D E., Greenberg S M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004 164 8 880-884
18. Davis S M., Broderick J, Hennerici M et al, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006 66 8 1175-1181
19. Leira R, Dávalos A, Silva Y et al, Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004 63 3 461-467
20. Hart R G., Pearce L A., Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 146 12 857-867
21. Stafford R S., Singer D E. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996 156 22 2537-2541
22. Fang M C., Stafford R S., Ruskin J N., Singer D E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004 164 1 55-60
23. Flaherty M L., Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007 68 2 116-121
24. Kucher N, Castellanos L R., Quiroz R, Koo S, Fanikos J, Goldhaber S Z. Time trends in warfarin-associated hemorrhage. Am J Cardiol 2004 94 3 403-406
25. Lawrentschuk N, Kariappa S, Kaye A H. Spontaneous intracerebral haemorrhages-warfarin as a risk factor. J Clin Neurosci 2003 10 5 550-552
26. Flaherty M L., Haverbusch M, Sekar P et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006 5 3 197-201
27. Hart R G., Boop B S., Anderson D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995 26 8 1471-1477
28. Hart R G., Tonarelli S B., Pearce L A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005 36 7 1588-1593
29. Connolly S J., Ezekowitz M D., Yusuf S et al, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 12 1139-1151
30. Mohr J P., Thompson J LP, Lazar R M. et al, Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001 345 20 1444-1451
31. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997 42 6 857-865
32. Gorter J W., For the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Study Groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999 53 6 1319-1327
33. Själander A, Engström G, Berntorp E, Svensson P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med 2003 254 5 434-438
34. Petty G W., Brown R DJ Jr, Whisnant J P., Sicks J D., O'Fallon W M., Wiebers D O. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med 1999 130 1 14-22
35. Caro J J., Flegel K M., Orejuela M E., Kelley H E., Speckman J L., Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 1999 161 5 493-497
36. Go A S., Hylek E M., Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 290 20 2685-2692
37. Hylek E M., Evans-Molina C, Shea C, Henault L E., Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 115 21 2689-2696
38. Fang M C., Chang Y, Hylek E M. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004 141 10 745-752
39. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997 42 6 857-865
40. Hart R G., Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999 9 4 215-217
41. Dentali F, Douketis J D., Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007 167 2 117-124
42. Flaker G C., Gruber M, Connolly S J. et al, SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006 152 5 967-973
43. Naka H, Nomura E, Wakabayashi S et al. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis. AJNR Am J Neuroradiol 2004 25 5 714-719
44. Jeerakathil T, Wolf P A., Beiser A et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004 35 8 1831-1835
45. Greenberg S M., Finklestein S P., Schaefer P W. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996 46 6 1751-1754
46. Roob G, Schmidt R, Kapeller P, Lechner A, Hartung H P., Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999 52 5 991-994
47. Greenberg S M., Eng J A., Ning M, Smith E E., Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004 35 6 1415-1420 (Pubitemid 38697468)
48. Lee S H., Ryu W S., Roh J K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 2009 72 2 171-176
49. Eckman M H., Wong L KS, Soo Y OY et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help? Stroke 2008 39 12 3308-3315
50. Pfleger M J., Hardee E P., Contant C FJ Jr, Hayman L A. Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas. AJNR Am J Neuroradiol 1994 15 2 217-223
51. Toyoda K, Okada Y, Ibayashi S et al. Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovasc Dis 2007 23 2-3 109-116
52. Flibotte J J., Hagan N, O'Donnell J, Greenberg S M., Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004 63 6 1059-1064
53. Rådberg J A., Olsson J E., Rådberg C T. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991 22 5 571-576
54. Flaherty M L., Tao H, Haverbusch M et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008 71 14 1084-1089
55. Sjöblom L, Hårdemark H-G, Lindgren A et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001 32 11 2567-2574
56. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P, CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008 39 11 2993-2996
57. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003 89 2 278-283
58. Morgenstern L B., Hemphill J CI, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010 41 2108-2129
59. Anderson C S., Huang Y, Wang J G. et al, INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008 7 5 391-399
60. Hankey G J., Hon C. Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials. Stroke 1997 28 11 2126-2132
61. Mendelow A D., Gregson B A., Fernandes H M. et al, STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005 365 9457 387-397
62. Morgenstern L B., Demchuk A M., Kim D H., Frankowski R F., Grotta J C. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology 2001 56 10 1294-1299
63. Mayer S A. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 2003 34 1 224-229
64. Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 2010 36 5 485-492
65. Friederich P W., Henny C P., Messelink E J. et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003 361 9353 201-205
66. Mayer S A., Brun N C., Begtrup K et al, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005 352 8 777-785
67. Mayer S A., Brun N C., Begtrup K et al, FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008 358 20 2127-2137
68. Diringer M N., Skolnick B E., Mayer S A. et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010 41 1 48-53
69. Hanley J P. Warfarin reversal. J Clin Pathol 2004 57 11 1132-1139
70. Ansell J, Hirsh J, Hylek E et al. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 6 Suppl 160S-198S (Pubitemid 351892967)
71. Watson H G., Baglin T, Laidlaw S L., Makris M, Preston F E. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001 115 1 145-149
72. Fiore L D., Scola M A., Cantillon C E., Brophy M T. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001 11 2 175-183
73. Crowther M A., Douketis J D., Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002 137 4 251-254
74. Raj G, Kumar R, McKinney W P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999 159 22 2721-2724
75. Whitling A M., Bussey H I., Lyons R M. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998 158 19 2136-2140
76. Flaherty M L., Adeoye O, Sekar P et al. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke 2009 40 5 1738-1742
77. Fredriksson K, Norrving B, Strömblad L G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992 23 7 972-977
78. Cartmill M, Dolan G, Byrne J L., Byrne P O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000 14 5 458-461
79. Tanaka K A., Szlam F, Dickneite G, Levy J H. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008 122 1 117-123
80. Freeman W D., Brott T G., Barrett K M. et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004 79 12 1495-1500
81. Robinson M T., Rabinstein A A., Meschia J F., Freeman W D. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke 2010 41 7 1459-1463
82. Schulman S, Bijsterveld N R. Anticoagulants and their reversal. Transfus Med Rev 2007 21 1 37-48
83. Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 3 Suppl 188S-203S
84. Eikelboom J W., Weitz J I. New anticoagulants. Circulation 2010 121 13 1523-1532
85. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilatea novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 103 6 1116-1127
86. Steiner T, Kaste M, Forsting M et al, European Stroke Initiative Writing Committee Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. Cerebrovasc Dis 2006 22 4 294-316 (Pubitemid 44338094)
87. Baglin T P., Keeling D M., Watson H G., British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition2005 update. Br J Haematol 2006 132 3 277-285
88. Baker R I., Coughlin P B., Gallus A S., Harper P L., Salem H H., Wood E M., Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004 181 9 492-497